Scandinavian Biopharma enters into an exclusive agreement with Flynn Pharma for ViperaTAb
Scandinavian Biopharma today announces that the company has entered into an exclusive agreement with Flynn Pharma for the viper antivenom ViperaTAb.
Under the new agreement, Scandinavian Biopharma will have exclusive rights to service and make ViperaTAb available for emergency use in the Nordics, Baltic States and Germany.
“We are very pleased to strengthen our portfolio with an important antivenom for Northern Europe” says Björn Sjöstrand, CEO at Scandinavian Biopharma. “
ViperaTAb is not registered in the European Union but is available under special permission.